Welcome to our dedicated page for NEOGENOMICS SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NeoGenomics Inc. executive vice president and general counsel Alicia C. Olivo reported new equity awards. On March 1, 2026, she received 147,804 stock options and 89,013 restricted stock units as compensation, both granted at an exercise/issue price of $0.00 per share.
The stock options are described as premium-price options, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest in equal installments over the first three anniversaries of the grant date, and once vested, the related common shares are not subject to expiration.
NeoGenomics Inc. reported that President & Chief Operating Officer Warren Stone received new equity awards. On March 1, 2026, he was granted 253,378 stock options and 152,594 restricted stock units, both vesting ratably over the first three anniversary dates of the grant.
The stock option grant was structured as a premium-price option, with the exercise price set at 110% of the February 27, 2026 closing share price. Footnotes also describe Mr. Stone’s existing stock options, restricted stock units, and performance stock units granted between 2022 and 2025, which vest over multi‑year and performance-based schedules.
NeoGenomics Inc. reported that Chief Executive Officer Anthony P. Zook received new equity awards. On March 1, 2026, he was granted 675,676 stock options and 406,918 restricted stock units at no cost per unit. The options are premium-price awards, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest ratably over the first three anniversaries of the grant date, tying most of the value to multi‑year service and performance. Once vested, the underlying common shares are not subject to expiration. Footnotes also reference earlier premium-price grants on April 1, 2025, indicating a continuing emphasis on performance-oriented, at-risk compensation for the CEO.
NeoGenomics Inc. Chief Financial Officer Abhishek Jain reported his initial equity holdings. On January 13, 2026, he was granted 183,578 stock options and 110,088 restricted stock units, which vest ratably over the first three anniversaries of the grant date. Once vested, the underlying common shares are not subject to expiration.
NeoGenomics President & Chief Operating Officer Warren Stone reported equity award vesting and related share-withholding transactions. On February 21 and 23, 2026, restricted stock units converted into 36,548 shares of common stock at no cash exercise price.
To cover tax obligations tied to these RSU releases, 10,465 common shares were disposed of through issuer share withholding rather than open-market sales. Following these transactions, Stone directly owned 147,714 shares of NeoGenomics common stock, along with various stock option, restricted stock unit, and performance stock unit holdings described in the filing footnotes.
NeoGenomics Chief Financial Officer Jeffrey Scott Sherman reported equity award activity, not open‑market trading. On February 21 and February 23, he converted restricted stock units into common stock in transactions coded as exercises or conversions. The filing also shows shares withheld and disposed of to cover tax obligations related to these RSU releases. After these transactions, he directly owned 220,009 shares of common stock, alongside multiple outstanding stock option, restricted stock unit, and performance stock unit awards that vest over future years.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported equity award activity. On February 21 and 23, 2026, she converted a total of 29,522 restricted stock units into an equal number of NeoGenomics common shares at no cash exercise price. To cover tax withholding on these vestings, 11,618 common shares were disposed of through share withholding rather than open-market sales. After these transactions, she directly held 93,224 shares of common stock, alongside multiple outstanding stock option, restricted stock unit, and performance stock unit awards that continue to vest over time.
NeoGenomics Chief Accounting Officer Greg D. Aunan reported equity compensation activity. On February 21, 2026, he exercised 6,323 restricted stock units, converting them into the same number of shares of common stock at $0.00 per share, reflecting vesting of prior RSU grants. On the same date, 1,875 common shares were withheld and disposed of to cover tax obligations related to the RSU release, rather than an open-market sale. Following these transactions, he directly held 22,027 shares of common stock and maintained multiple outstanding stock option and RSU awards that vest over future anniversaries of their respective grant dates.
NeoGenomics, Inc. is an oncology-focused diagnostics company that runs CAP-accredited and CLIA-certified labs across the U.S. and an ISO-certified lab in Cambridge, U.K. It offers cytogenetics, FISH, flow cytometry, IHC, molecular and NGS panels, MRD testing, morphologic analysis, pharma trial support, and oncology data solutions.
The company serves community oncologists, pathologists, hospitals, reference labs, academic centers, and pharmaceutical sponsors through a single operating segment. Key 2026 priorities include expanding therapy selection and MRD products, deepening its community oncology footprint, improving automation and customer experience, and strengthening culture and cross-functional collaboration.
NeoGenomics operates in a rapidly evolving precision oncology market with growing demand for predictive and MRD testing, but faces intense competition, significant regulatory oversight, reimbursement pressure, data privacy obligations, and operational risks outlined in extensive risk factors.
NeoGenomics, Inc. reported fourth-quarter and full-year 2025 results showing solid revenue growth but continued net losses. Fourth-quarter revenue rose 11% to $190.2 million, with full-year revenue up 10% to $727.3 million, driven by higher test volumes and a shift toward higher value oncology diagnostics.
Fourth-quarter net loss improved to $9.9 million from $15.3 million, while full-year net loss widened to $108.0 million due to items such as impairment and litigation costs. Non-GAAP adjusted EBITDA was positive $13.4 million in Q4 and $43.4 million for 2025, both modestly higher than 2024.
The company highlighted strong growth in next‑generation sequencing, progress on its RaDaR ST minimal residual disease assay, and a successful resolution of RaDaR ST patent litigation. For 2026, NeoGenomics guides revenue to $793–801 million, a smaller GAAP net loss of $50–63 million, and adjusted EBITDA of $55–57 million.